MRSA Nanobody
Methicillin-resistant Staphylococcus aureus infection
Pre-clinicalActive
Key Facts
Indication
Methicillin-resistant Staphylococcus aureus infection
Phase
Pre-clinical
Status
Active
Company
About VicuTec Biologicals
VicuTec Biologicals is a private, preclinical-stage biotech based in Munich and Dortmund, Germany, developing a robust nanobody platform. The company's technology, originating from the Max Planck Institute and University Medical Center Göttingen, enables rapid, cost-effective production of highly potent nanobodies in microbial systems. Its initial pipeline targets major infectious diseases including COVID-19, MRSA, Tuberculosis, and Malaria, with backing from the EU Malaria Fund and strategic academic partnerships.
View full company profileTherapeutic Areas
Other Methicillin-resistant Staphylococcus aureus infection Drugs
| Drug | Company | Phase |
|---|---|---|
| MRSA Vaccine | VLP Biotech | Pre-clinical |